The Firmicutes/Bacteroidetes ratio of the human gut microbiota is associated with prostate enlargement
Background The pathophysiology of the prostate enlargement underlying lower urinary tract symptoms is unknown. Meanwhile, the gut microbiota can contribute to various host conditions. We hypothesized that the gut microbiota plays a role in prostate enlargement. Methods We included 128 patients who u...
Saved in:
| Published in: | The Prostate Vol. 81; no. 16; pp. 1287 - 1293 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Wiley Subscription Services, Inc
01.12.2021
|
| Subjects: | |
| ISSN: | 0270-4137, 1097-0045, 1097-0045 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background
The pathophysiology of the prostate enlargement underlying lower urinary tract symptoms is unknown. Meanwhile, the gut microbiota can contribute to various host conditions. We hypothesized that the gut microbiota plays a role in prostate enlargement.
Methods
We included 128 patients who underwent prostate biopsies at our hospitals between December 2018 and March 2020, excluding those who had used antibiotics within the past 6 months and those who were diagnosed with prostate cancer of cT3 or higher. Patients with prostate volumes ≥30 ml were defined as the prostate‐enlargement (PE) group; those with prostate volumes <30 ml were defined as the non‐PE group. Their gut microbiotas were analyzed via 16S rRNA metagenomic analyses of rectal swab samples and were compared between the groups.
Results
The PE group included 66 patients; the non‐PE group included 62 patients. Age, body mass index, and prostate‐specific antigen levels did not significantly differ between the groups. Linear discriminant analysis effect size analysis indicated a higher proportion of Firmicutes and Actinobacteria in the PE group and a higher proportion of Bacteroidetes in the non‐PE group. The Firmicutes/Bacteroidetes (F/B) ratio was significantly higher in the PE group than in the non‐PE group (2.21 ± 0.39 vs. 1.61 ± 0.40, p = 0.015).
Conclusion
The F/B ratio of the gut microbiota was associated with prostate enlargement. Although the detailed mechanisms are unclear, the gut microbiota might affect prostate enlargement. |
|---|---|
| AbstractList | The pathophysiology of the prostate enlargement underlying lower urinary tract symptoms is unknown. Meanwhile, the gut microbiota can contribute to various host conditions. We hypothesized that the gut microbiota plays a role in prostate enlargement.
We included 128 patients who underwent prostate biopsies at our hospitals between December 2018 and March 2020, excluding those who had used antibiotics within the past 6 months and those who were diagnosed with prostate cancer of cT3 or higher. Patients with prostate volumes ≥30 ml were defined as the prostate-enlargement (PE) group; those with prostate volumes <30 ml were defined as the non-PE group. Their gut microbiotas were analyzed via 16S rRNA metagenomic analyses of rectal swab samples and were compared between the groups.
The PE group included 66 patients; the non-PE group included 62 patients. Age, body mass index, and prostate-specific antigen levels did not significantly differ between the groups. Linear discriminant analysis effect size analysis indicated a higher proportion of Firmicutes and Actinobacteria in the PE group and a higher proportion of Bacteroidetes in the non-PE group. The Firmicutes/Bacteroidetes (F/B) ratio was significantly higher in the PE group than in the non-PE group (2.21 ± 0.39 vs. 1.61 ± 0.40, p = 0.015).
The F/B ratio of the gut microbiota was associated with prostate enlargement. Although the detailed mechanisms are unclear, the gut microbiota might affect prostate enlargement. The pathophysiology of the prostate enlargement underlying lower urinary tract symptoms is unknown. Meanwhile, the gut microbiota can contribute to various host conditions. We hypothesized that the gut microbiota plays a role in prostate enlargement.BACKGROUNDThe pathophysiology of the prostate enlargement underlying lower urinary tract symptoms is unknown. Meanwhile, the gut microbiota can contribute to various host conditions. We hypothesized that the gut microbiota plays a role in prostate enlargement.We included 128 patients who underwent prostate biopsies at our hospitals between December 2018 and March 2020, excluding those who had used antibiotics within the past 6 months and those who were diagnosed with prostate cancer of cT3 or higher. Patients with prostate volumes ≥30 ml were defined as the prostate-enlargement (PE) group; those with prostate volumes <30 ml were defined as the non-PE group. Their gut microbiotas were analyzed via 16S rRNA metagenomic analyses of rectal swab samples and were compared between the groups.METHODSWe included 128 patients who underwent prostate biopsies at our hospitals between December 2018 and March 2020, excluding those who had used antibiotics within the past 6 months and those who were diagnosed with prostate cancer of cT3 or higher. Patients with prostate volumes ≥30 ml were defined as the prostate-enlargement (PE) group; those with prostate volumes <30 ml were defined as the non-PE group. Their gut microbiotas were analyzed via 16S rRNA metagenomic analyses of rectal swab samples and were compared between the groups.The PE group included 66 patients; the non-PE group included 62 patients. Age, body mass index, and prostate-specific antigen levels did not significantly differ between the groups. Linear discriminant analysis effect size analysis indicated a higher proportion of Firmicutes and Actinobacteria in the PE group and a higher proportion of Bacteroidetes in the non-PE group. The Firmicutes/Bacteroidetes (F/B) ratio was significantly higher in the PE group than in the non-PE group (2.21 ± 0.39 vs. 1.61 ± 0.40, p = 0.015).RESULTSThe PE group included 66 patients; the non-PE group included 62 patients. Age, body mass index, and prostate-specific antigen levels did not significantly differ between the groups. Linear discriminant analysis effect size analysis indicated a higher proportion of Firmicutes and Actinobacteria in the PE group and a higher proportion of Bacteroidetes in the non-PE group. The Firmicutes/Bacteroidetes (F/B) ratio was significantly higher in the PE group than in the non-PE group (2.21 ± 0.39 vs. 1.61 ± 0.40, p = 0.015).The F/B ratio of the gut microbiota was associated with prostate enlargement. Although the detailed mechanisms are unclear, the gut microbiota might affect prostate enlargement.CONCLUSIONThe F/B ratio of the gut microbiota was associated with prostate enlargement. Although the detailed mechanisms are unclear, the gut microbiota might affect prostate enlargement. BackgroundThe pathophysiology of the prostate enlargement underlying lower urinary tract symptoms is unknown. Meanwhile, the gut microbiota can contribute to various host conditions. We hypothesized that the gut microbiota plays a role in prostate enlargement.MethodsWe included 128 patients who underwent prostate biopsies at our hospitals between December 2018 and March 2020, excluding those who had used antibiotics within the past 6 months and those who were diagnosed with prostate cancer of cT3 or higher. Patients with prostate volumes ≥30 ml were defined as the prostate‐enlargement (PE) group; those with prostate volumes <30 ml were defined as the non‐PE group. Their gut microbiotas were analyzed via 16S rRNA metagenomic analyses of rectal swab samples and were compared between the groups.ResultsThe PE group included 66 patients; the non‐PE group included 62 patients. Age, body mass index, and prostate‐specific antigen levels did not significantly differ between the groups. Linear discriminant analysis effect size analysis indicated a higher proportion of Firmicutes and Actinobacteria in the PE group and a higher proportion of Bacteroidetes in the non‐PE group. The Firmicutes/Bacteroidetes (F/B) ratio was significantly higher in the PE group than in the non‐PE group (2.21 ± 0.39 vs. 1.61 ± 0.40, p = 0.015).ConclusionThe F/B ratio of the gut microbiota was associated with prostate enlargement. Although the detailed mechanisms are unclear, the gut microbiota might affect prostate enlargement. Background The pathophysiology of the prostate enlargement underlying lower urinary tract symptoms is unknown. Meanwhile, the gut microbiota can contribute to various host conditions. We hypothesized that the gut microbiota plays a role in prostate enlargement. Methods We included 128 patients who underwent prostate biopsies at our hospitals between December 2018 and March 2020, excluding those who had used antibiotics within the past 6 months and those who were diagnosed with prostate cancer of cT3 or higher. Patients with prostate volumes ≥30 ml were defined as the prostate‐enlargement (PE) group; those with prostate volumes <30 ml were defined as the non‐PE group. Their gut microbiotas were analyzed via 16S rRNA metagenomic analyses of rectal swab samples and were compared between the groups. Results The PE group included 66 patients; the non‐PE group included 62 patients. Age, body mass index, and prostate‐specific antigen levels did not significantly differ between the groups. Linear discriminant analysis effect size analysis indicated a higher proportion of Firmicutes and Actinobacteria in the PE group and a higher proportion of Bacteroidetes in the non‐PE group. The Firmicutes/Bacteroidetes (F/B) ratio was significantly higher in the PE group than in the non‐PE group (2.21 ± 0.39 vs. 1.61 ± 0.40, p = 0.015). Conclusion The F/B ratio of the gut microbiota was associated with prostate enlargement. Although the detailed mechanisms are unclear, the gut microbiota might affect prostate enlargement. |
| Author | Takezawa, Kentaro Banno, Eri Nonomura, Norio Takada, Shingo Okada, Koichi Uemura, Hirotsugu Nakamura, Shota Kojima, Yoshiyuki Matsushita, Makoto Fujita, Kazutoshi Fukuhara, Shinichiro Kiuchi, Hiroshi Hatano, Koji Motooka, Daisuke Shimizu, Nobutaka Takao, Tetsuya |
| Author_xml | – sequence: 1 givenname: Kentaro orcidid: 0000-0003-1137-1846 surname: Takezawa fullname: Takezawa, Kentaro organization: Osaka University Graduate School of Medicine – sequence: 2 givenname: Kazutoshi orcidid: 0000-0002-6774-7497 surname: Fujita fullname: Fujita, Kazutoshi email: kazu.fujita2@gmail.com organization: Kindai University Faculty of Medicine – sequence: 3 givenname: Makoto orcidid: 0000-0002-7491-9410 surname: Matsushita fullname: Matsushita, Makoto organization: Osaka University Graduate School of Medicine – sequence: 4 givenname: Daisuke surname: Motooka fullname: Motooka, Daisuke organization: Osaka University – sequence: 5 givenname: Koji surname: Hatano fullname: Hatano, Koji organization: Osaka University Graduate School of Medicine – sequence: 6 givenname: Eri surname: Banno fullname: Banno, Eri organization: Kindai University Faculty of Medicine – sequence: 7 givenname: Nobutaka surname: Shimizu fullname: Shimizu, Nobutaka organization: Kindai University Faculty of Medicine – sequence: 8 givenname: Tetsuya surname: Takao fullname: Takao, Tetsuya organization: Osaka General Medical Center – sequence: 9 givenname: Shingo surname: Takada fullname: Takada, Shingo organization: Osaka Police Hospital – sequence: 10 givenname: Koichi surname: Okada fullname: Okada, Koichi organization: Osaka University Graduate School of Medicine – sequence: 11 givenname: Shinichiro surname: Fukuhara fullname: Fukuhara, Shinichiro organization: Osaka University Graduate School of Medicine – sequence: 12 givenname: Hiroshi surname: Kiuchi fullname: Kiuchi, Hiroshi organization: Osaka University Graduate School of Medicine – sequence: 13 givenname: Hirotsugu surname: Uemura fullname: Uemura, Hirotsugu organization: Kindai University Faculty of Medicine – sequence: 14 givenname: Shota surname: Nakamura fullname: Nakamura, Shota organization: Osaka University – sequence: 15 givenname: Yoshiyuki surname: Kojima fullname: Kojima, Yoshiyuki organization: Fukushima Medical University – sequence: 16 givenname: Norio surname: Nonomura fullname: Nonomura, Norio organization: Osaka University Graduate School of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34516694$$D View this record in MEDLINE/PubMed |
| BookMark | eNp90U1L3kAQB_BFLPXR9uIHkAUvUojOviXZo0ptC4Ki9rxskonPSpLV3Q3it3fjoxcpPQ0DvxmG_-yS7clPSMg-g2MGwE8eg4_HXHIutsiKga4KAKm2yQp4BYVkotohuzE-AGQO_CvZEVKxstRyRfq7NdILF0bXzgnjyZltEwbvOswdDTY5T31PU1brebQTvZ8TzTj4xvlkqYvUxuhbZxN29NmlNV3OSbmlOA023OOIU_pGvvR2iPj9ve6Rvxc_785_F5dXv_6cn14WrVCVKBpkTJRty6pKi0ZriWgZB1R11dR1ybDspVRdz3rUnJW2boQG1ZW8q1XDexR75GizNx_xNGNMZnSxxWGwE_o5Gq4qrrgGxjM9_EQf_BymfF1WGrQoZb2og3c1NyN25jG40YYX85FgBrABOZIYA_amdWmJbUrBusEwMMuTzJKKeXtSHvnxaeRj6z8x2-BnN-DLf6S5vrm63cy8AgodomU |
| CitedBy_id | crossref_primary_10_1111_iju_15446 crossref_primary_10_1016_j_molmed_2025_03_015 crossref_primary_10_1186_s40001_024_02034_9 crossref_primary_10_3390_md22110485 crossref_primary_10_1016_j_micres_2023_127596 crossref_primary_10_1186_s12866_023_02925_7 crossref_primary_10_3389_fcimb_2022_1048319 crossref_primary_10_3390_jcm12062216 crossref_primary_10_3390_cancers14163988 crossref_primary_10_5534_wjmh_220202 crossref_primary_10_1111_iju_15518 crossref_primary_10_1016_j_csbj_2023_02_027 crossref_primary_10_1002_pros_24457 crossref_primary_10_1002_pros_24776 crossref_primary_10_1016_j_fbio_2024_104354 crossref_primary_10_1002_ijc_34028 crossref_primary_10_1016_j_biopha_2023_114892 crossref_primary_10_5534_wjmh_210190 crossref_primary_10_3389_fmicb_2022_911408 crossref_primary_10_3390_nu15030682 crossref_primary_10_1080_21505594_2024_2313410 crossref_primary_10_3389_fmicb_2022_978644 crossref_primary_10_1128_aem_00372_25 crossref_primary_10_1016_j_nutres_2024_01_012 crossref_primary_10_1038_s41443_022_00569_1 crossref_primary_10_1016_j_mcp_2022_101874 crossref_primary_10_1007_s10120_025_01587_w crossref_primary_10_1016_j_crmicr_2025_100420 crossref_primary_10_3390_diagnostics12081862 crossref_primary_10_3389_fmed_2025_1511612 crossref_primary_10_1111_iju_14894 crossref_primary_10_1128_spectrum_00696_24 crossref_primary_10_3389_fcimb_2024_1431088 crossref_primary_10_1186_s40779_022_00373_4 crossref_primary_10_1002_jsp2_70005 crossref_primary_10_1038_s41598_024_54293_5 crossref_primary_10_1016_j_aquaculture_2023_739925 crossref_primary_10_1016_j_heliyon_2024_e38302 crossref_primary_10_1038_s41598_025_00466_9 crossref_primary_10_1002_pros_24675 crossref_primary_10_3390_foods13223647 crossref_primary_10_3390_cancers15051375 crossref_primary_10_1016_j_micpath_2024_106667 crossref_primary_10_3389_fmicb_2024_1445304 crossref_primary_10_1007_s40005_022_00600_z crossref_primary_10_1002_jor_25635 crossref_primary_10_3390_ijms241411634 crossref_primary_10_3390_life14101227 crossref_primary_10_3390_molecules30112372 |
| Cites_doi | 10.1128/mBio.01283-14 10.1016/S0022-5347(01)61784-1 10.1016/j.juro.2015.03.103 10.1038/4441022a 10.1016/j.juro.2017.08.001 10.1002/pros.21081 10.1002/pros.23713 10.1038/s41467-019-13467-w 10.1158/0008-5472.CAN-20-4090 10.1016/j.urology.2016.02.043 10.1016/j.eururo.2011.11.013 10.3390/ijms21041447 10.1038/s41591-020-01183-8 10.1126/science.1110591 10.1038/nn.4476 10.1136/gutjnl-2015-309990 10.1038/nm.4185 10.1007/s11934-019-0904-6 10.1111/bju.12745 10.1002/pros.23971 10.1128/JCM.02876-13 10.1016/j.eururo.2009.09.035 10.5114/aoms.2015.50970 10.1093/dnares/dsw002 10.1111/cas.14998 10.1016/j.eururo.2018.06.033 10.3390/microorganisms8111715 10.1016/S0022-5347(05)00408-8 10.1002/ana.25250 10.1186/s12894-017-0211-9 |
| ContentType | Journal Article |
| Copyright | 2021 Wiley Periodicals LLC 2021 Wiley Periodicals LLC. |
| Copyright_xml | – notice: 2021 Wiley Periodicals LLC – notice: 2021 Wiley Periodicals LLC. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TO 8FD FR3 H94 K9. P64 RC3 7X8 |
| DOI | 10.1002/pros.24223 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Genetics Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1097-0045 |
| EndPage | 1293 |
| ExternalDocumentID | 34516694 10_1002_pros_24223 PROS24223 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .3N .GA 05W 0R~ 10A 123 1L6 1OB 1OC 1ZS 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AAXRX AAYCA AAZKR ABCQN ABCUV ABIJN ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EMOBN F00 F01 F04 F5P FUBAC G-S G.N GNP GODZA H.X HBH HGLYW HHY HHZ HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SUPJJ SV3 TEORI UB1 V2E W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WWO WXI WXSBR XG1 XV2 ZZTAW ~IA ~WT .GJ .Y3 31~ 3O- 53G AAMMB AANHP AASGY AAYXX ABEML ACBWZ ACRPL ACSCC ACYXJ ADNMO AEFGJ AEYWJ AFFNX AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY AIQQE ASPBG AVWKF AZFZN CITATION EJD FEDTE HF~ HVGLF LW6 M6P O8X PALCI RIWAO RJQFR SAMSI ZGI ZXP CGR CUY CVF ECM EIF NPM 7T5 7TO 8FD FR3 H94 K9. P64 RC3 7X8 |
| ID | FETCH-LOGICAL-c3573-be1136cc17793b994eea120e587b8861e6f445df1fe9216a8b3905d62d85b2fe3 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 55 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000695237100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0270-4137 1097-0045 |
| IngestDate | Fri Jul 11 08:30:29 EDT 2025 Sat Nov 29 14:41:51 EST 2025 Wed Feb 19 02:26:45 EST 2025 Sat Nov 29 01:37:01 EST 2025 Tue Nov 18 21:54:31 EST 2025 Wed Jan 22 16:28:41 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 16 |
| Keywords | bacteria microbiome benign prostatic hyperplasia |
| Language | English |
| License | 2021 Wiley Periodicals LLC. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3573-be1136cc17793b994eea120e587b8861e6f445df1fe9216a8b3905d62d85b2fe3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-7491-9410 0000-0002-6774-7497 0000-0003-1137-1846 |
| PMID | 34516694 |
| PQID | 2590936482 |
| PQPubID | 1016443 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_2572529012 proquest_journals_2590936482 pubmed_primary_34516694 crossref_citationtrail_10_1002_pros_24223 crossref_primary_10_1002_pros_24223 wiley_primary_10_1002_pros_24223_PROS24223 |
| PublicationCentury | 2000 |
| PublicationDate | December 1, 2021 2021-12-00 20211201 |
| PublicationDateYYYYMMDD | 2021-12-01 |
| PublicationDate_xml | – month: 12 year: 2021 text: December 1, 2021 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | The Prostate |
| PublicationTitleAlternate | Prostate |
| PublicationYear | 2021 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2012; 61 2021; 27 2017; 20 2010; 57 2019; 10 2019; 79 2015; 11 2020; 80 2006; 175 2018; 84 2016; 92 2020; 8 2018; 199 2015; 194 2014; 5 2015; 115 2019; 20 2021 2017; 17 1999; 161 2016; 65 2005; 308 2018; 74 2020; 21 2010; 70 2014; 52 2021; 81 2006; 444 2016; 23 2016; 22 e_1_2_10_23_1 e_1_2_10_24_1 e_1_2_10_21_1 e_1_2_10_22_1 e_1_2_10_20_1 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_12_1 e_1_2_10_9_1 e_1_2_10_13_1 e_1_2_10_10_1 e_1_2_10_11_1 e_1_2_10_31_1 e_1_2_10_30_1 e_1_2_10_29_1 e_1_2_10_27_1 e_1_2_10_28_1 e_1_2_10_25_1 e_1_2_10_26_1 |
| References_xml | – volume: 23 start-page: 125 year: 2016 end-page: 133 article-title: The gut microbiome of healthy Japanese and its microbial and functional uniqueness publication-title: DNA Res – volume: 65 start-page: 330 year: 2016 end-page: 339 article-title: The gut microbiota and host health: a new clinical frontier publication-title: Gut – start-page: 3125 year: 2021 end-page: 3135 article-title: The gut microbiota associated with high‐Gleason prostate cancer publication-title: Cancer Sci – volume: 20 start-page: 145 year: 2017 end-page: 155 article-title: Interactions between the microbiota, immune and nervous systems in health and disease publication-title: Nat Neurosci – volume: 57 start-page: 123 year: 2010 end-page: 131 article-title: The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4‐year results from the CombAT study publication-title: Eur Urol – volume: 61 start-page: 560 year: 2012 end-page: 570 article-title: The correlation between metabolic syndrome and prostatic diseases publication-title: Eur Urol – volume: 84 start-page: 23 year: 2018 end-page: 36 article-title: Age‐related changes in the gut microbiota influence systemic inflammation and stroke outcome publication-title: Ann Neurol – volume: 20 start-page: 34 year: 2019 article-title: Implications of the genitourinary microbiota in prostatic disease publication-title: Curr Urol Rep – volume: 79 start-page: 81 year: 2019 end-page: 87 article-title: A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis publication-title: Prostate – volume: 11 start-page: 385 year: 2015 end-page: 394 article-title: Urinary microbiota in patients with prostate cancer and benign prostatic hyperplasia publication-title: Arch Med Sci – volume: 115 start-page: 508 year: 2015 end-page: 519 article-title: Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)—focus on the UK publication-title: BJU Int – volume: 22 start-page: 1079 year: 2016 end-page: 1089 article-title: Signals from the gut microbiota to distant organs in physiology and disease publication-title: Nat Med – volume: 92 start-page: 26 year: 2016 end-page: 32 article-title: The urinary microbiome differs significantly between patients with chronic prostatitis/chronic pelvic pain syndrome and controls as well as between patients with different clinical phenotypes publication-title: Urology – volume: 70 start-page: 473 year: 2010 end-page: 481 article-title: Monocyte chemotactic protein‐1 (MCP‐1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia publication-title: Prostate – volume: 52 start-page: 871 year: 2014 end-page: 876 article-title: Urine is not sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult female bladder publication-title: J Clin Microbiol – volume: 80 start-page: 577 year: 2020 end-page: 587 article-title: Screening for chronic prostatitis pathogens using high‐throughput next‐generation sequencing publication-title: Prostate – volume: 199 start-page: 161 year: 2018 end-page: 171 article-title: Profiling the urinary microbiome in men with positive versus negative biopsies for prostate cancer publication-title: J Urol – volume: 175 start-page: 1018 year: 2006 end-page: 1022 article-title: Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort publication-title: J Urol – volume: 444 start-page: 1022 year: 2006 end-page: 1023 article-title: Microbial ecology: human gut microbes associated with obesity publication-title: Nature – volume: 308 start-page: 1635 year: 2005 end-page: 1638 article-title: Microbiology: diversity of the human intestinal microbial flora publication-title: Science – volume: 74 start-page: 575 year: 2018 end-page: 582 article-title: Metabolic biosynthesis pathways identified from fecal microbiome associated with prostate cancer publication-title: Eur Urol – volume: 81 start-page: 4014 year: 2021 end-page: 4026 article-title: Gut microbiota‐derived short‐chain fatty acids promote prostate cancer growth via IGF‐1 signaling publication-title: Cancer Res – volume: 27 start-page: 321 year: 2021 end-page: 332 article-title: Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals publication-title: Nat Med – volume: 21 start-page: 90 year: 2020 end-page: 105 article-title: Influence of diet and nutrition on prostate cancer publication-title: Int J Mol Sci – volume: 161 start-page: 831 year: 1999 end-page: 834 article-title: Prostatic central zone volume, lower urinary tract symptom severity and peak urinary flow rates in community dwelling men publication-title: J Urol – volume: 5 year: 2014 article-title: The female urinary microbiome: a comparison of women with and without urgency urinary incontinence publication-title: mBio – volume: 10 start-page: 5521 year: 2019 article-title: Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection publication-title: Nat Commun – volume: 8 start-page: 1715 year: 2020 article-title: The influence of probiotics on the firmicutes/bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease publication-title: Microorganisms – volume: 194 start-page: 454 year: 2015 end-page: 461 article-title: Prostate biopsy markers of inflammation are associated with risk of clinical progression of benign prostatic hyperplasia: findings from the MTOPS study publication-title: J Urol – volume: 17 start-page: 22 year: 2017 article-title: Benign prostatic enlargement can be influenced by metabolic profile: results of a multicenter prospective study publication-title: BMC Urol – ident: e_1_2_10_21_1 doi: 10.1128/mBio.01283-14 – ident: e_1_2_10_31_1 doi: 10.1016/S0022-5347(01)61784-1 – ident: e_1_2_10_18_1 doi: 10.1016/j.juro.2015.03.103 – ident: e_1_2_10_12_1 doi: 10.1038/4441022a – ident: e_1_2_10_27_1 doi: 10.1016/j.juro.2017.08.001 – ident: e_1_2_10_17_1 doi: 10.1002/pros.21081 – ident: e_1_2_10_26_1 doi: 10.1002/pros.23713 – ident: e_1_2_10_28_1 doi: 10.1038/s41467-019-13467-w – ident: e_1_2_10_10_1 doi: 10.1158/0008-5472.CAN-20-4090 – ident: e_1_2_10_25_1 doi: 10.1016/j.urology.2016.02.043 – ident: e_1_2_10_5_1 doi: 10.1016/j.eururo.2011.11.013 – ident: e_1_2_10_16_1 doi: 10.3390/ijms21041447 – ident: e_1_2_10_7_1 doi: 10.1038/s41591-020-01183-8 – ident: e_1_2_10_11_1 doi: 10.1126/science.1110591 – ident: e_1_2_10_8_1 doi: 10.1038/nn.4476 – ident: e_1_2_10_6_1 doi: 10.1136/gutjnl-2015-309990 – ident: e_1_2_10_19_1 doi: 10.1038/nm.4185 – ident: e_1_2_10_22_1 doi: 10.1007/s11934-019-0904-6 – ident: e_1_2_10_2_1 doi: 10.1111/bju.12745 – ident: e_1_2_10_24_1 doi: 10.1002/pros.23971 – ident: e_1_2_10_20_1 doi: 10.1128/JCM.02876-13 – ident: e_1_2_10_4_1 doi: 10.1016/j.eururo.2009.09.035 – ident: e_1_2_10_23_1 doi: 10.5114/aoms.2015.50970 – ident: e_1_2_10_30_1 doi: 10.1093/dnares/dsw002 – ident: e_1_2_10_9_1 doi: 10.1111/cas.14998 – ident: e_1_2_10_14_1 doi: 10.1016/j.eururo.2018.06.033 – ident: e_1_2_10_15_1 doi: 10.3390/microorganisms8111715 – ident: e_1_2_10_3_1 doi: 10.1016/S0022-5347(05)00408-8 – ident: e_1_2_10_13_1 doi: 10.1002/ana.25250 – ident: e_1_2_10_29_1 doi: 10.1186/s12894-017-0211-9 |
| SSID | ssj0010002 |
| Score | 2.5482028 |
| Snippet | Background
The pathophysiology of the prostate enlargement underlying lower urinary tract symptoms is unknown. Meanwhile, the gut microbiota can contribute to... The pathophysiology of the prostate enlargement underlying lower urinary tract symptoms is unknown. Meanwhile, the gut microbiota can contribute to various... BackgroundThe pathophysiology of the prostate enlargement underlying lower urinary tract symptoms is unknown. Meanwhile, the gut microbiota can contribute to... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1287 |
| SubjectTerms | Antibiotics bacteria Bacteroidetes Bacteroidetes - isolation & purification benign prostatic hyperplasia Biopsy Biopsy - methods Biopsy - statistics & numerical data Body mass index Discriminant analysis Enlargement Firmicutes Firmicutes - isolation & purification Gastrointestinal Microbiome - physiology Gut microbiota Humans Intestinal microflora Male Metagenomics Metagenomics - methods microbiome Microbiota Middle Aged Neoplasm Staging Organ Size Patients Prostate Prostate - pathology Prostate cancer Prostatic Hyperplasia - diagnosis Prostatic Hyperplasia - microbiology Prostatic Neoplasms - microbiology Prostatic Neoplasms - pathology Prostatic Neoplasms - physiopathology Risk Factors RNA, Ribosomal, 16S - isolation & purification rRNA 16S Urinary tract |
| Title | The Firmicutes/Bacteroidetes ratio of the human gut microbiota is associated with prostate enlargement |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpros.24223 https://www.ncbi.nlm.nih.gov/pubmed/34516694 https://www.proquest.com/docview/2590936482 https://www.proquest.com/docview/2572529012 |
| Volume | 81 |
| WOSCitedRecordID | wos000695237100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Journals customDbUrl: eissn: 1097-0045 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0010002 issn: 0270-4137 databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3di9QwEB_u9kR88ftj9Twi-qLQ2zZpmgR88Wvx4TyP04N9K0k6kcLZldtd_34zabfHoQjiWyFTMmRmkl9n0t8AvMglYnC6yoJHTmVGnbmQy8zk3BquGh1sosw_UsfHerEwJzvwevsvTM8PMSbcKDLSfk0Bbt1qdkkaGjeY1WE8YLjYhT0eHVdOYO_96fzsaKwiULinHIvKoxpCjfSkfHb59tUD6TeUeRW0plNnfuv_9L0NNwe0yd707nEHdrC7C9c_DfX0exCil7B5G43tNxFzzt4m7uZl21A6liXnYMvAIkhkqZkf-7ZZs-9tT960tqxdMTvYFxtGOV1GChCAZdid0y1zyj7eh7P5h6_vPmZD54XMC6lE5pBavXhfqBi-zpgS0RY8R6mV07oqsAplKZtQBDS8qKx2wuSyqXijpeMBxQOYdMsOHwHzcbsNEQMU0onSx68T6wRyR-3HrRLcTeHldvlrP9CSU3eM87onVOY16V2nhZvC81H2R0_G8Uep_a0V6yEg44g0uRFVqfkUno3DMZSoPmI7XG5IRnFJdeUo87C3_jiNoIbGlSmn8CoZ-S_z1yenn7-kp8f_IvwEbnC6L5OuyuzDZH2xwadwzf9ct6uLA9hVC30wOPgv1u3-Jg |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5Bi4AL78dCASO4gBQ2sePYPvJaFbFdqtJKvUW2M0aRShZ1d_n9eJw0VQVCQtwieSKPPA9PZibfALzMJWJwusqCR05lRp25kMvM5NwarhodbILMn6vFQh8fm_2hN4f-henxIcaEG1lG8tdk4JSQnp6jhkYPs3oTbxguLsN2GfUoKvj2h4PZ0XwsI5C9pySLyiMfQo34pHx6_vbFG-m3MPNi1JqundnN_2T4FtwY4k32tleQ23AJuztwdW-oqN-FEPWEzdoobr-JUef0XUJvXrYNJWRZUg-2DCyGiSyN82PfNmv2ve3hm9aWtStmBwljwyiry4gBCmEZdifUZ075x3twNPt4-H43G2YvZF5IJTKHNOzF-0JFA3bGlIi24DlKrZzWVYFVKEvZhCKg4UVltRMml03FGy0dDyjuw1a37PAhMB8dbohRQCGdKH38PrFOIHc0gNwqwd0EXp2df-0HYHKaj3FS95DKvCa-63RwE3gx0v7o4Tj-SLVzJsZ6MMm4Ik1uRFVqPoHn43I0JqqQ2A6XG6JRXFJlOdI86MU_biNopHFlygm8TlL-y_71_sGXr-np0b8QP4Nru4d783r-afH5MVzn1D2TGmd2YGt9usEncMX_XLer06eDnv8CDGMBPQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3di9QwEB90Tw5f_P5YPTWiLwq9bZOmSR7Vsyiu63J6cG-lSSdSOLvH7a5_v5m01-NQBPGtkCkZMh-Zzkx_A_AylYje6iLxDjmVGXVifSoTk_LacNVoX0fI_LlaLPTxsVkOvTn0L0yPDzEm3Mgyor8mA8fTxs8uUEODh1nvhxuGi6uwk9MUmQnsHByWR_OxjED2HpMsKg18CDXik_LZxduXb6TfwszLUWu8dsqb_8nwLbgxxJvsTa8gt-EKdndg9_NQUb8LPugJK9sgbrcNUefsbURvXrUNJWRZVA-28iyEiSyO82Pftxv2o-3hmzY1a9esHiSMDaOsLiMGKIRl2J1QnznlH-_BUfn-27sPyTB7IXFCKpFYpGEvzmUqGLA1JkesM56i1MpqXWRY-DyXjc88Gp4VtbbCpLIpeKOl5R7FfZh0qw4fAnPB4foQBWTSityF75PaCuSWBpDXSnA7hVfn51-5AZic5mOcVD2kMq-I7yoe3BRejLSnPRzHH6n2zsVYDSYZVqRJjShyzafwfFwOxkQVkrrD1ZZoFJdUWQ40D3rxj9sIGmlcmHwKr6OU_7J_tTz88jU-PfoX4mewuzwoq_nHxafHcJ1T80zsm9mDyeZsi0_gmvu5addnTwc1_wWWeAC4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Firmicutes%2FBacteroidetes+ratio+of+the+human+gut+microbiota+is+associated+with+prostate+enlargement&rft.jtitle=The+Prostate&rft.au=Takezawa%2C+Kentaro&rft.au=Fujita%2C+Kazutoshi&rft.au=Matsushita%2C+Makoto&rft.au=Motooka%2C+Daisuke&rft.date=2021-12-01&rft.issn=1097-0045&rft.eissn=1097-0045&rft.volume=81&rft.issue=16&rft.spage=1287&rft_id=info:doi/10.1002%2Fpros.24223&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-4137&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-4137&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-4137&client=summon |